Better High-Yield Dividend Stock: Altria or British American Tobacco?
Altria and British American Tobacco have nearly identical dividend yields, growth, and valuations today.
Smoke-free nicotine is the industry's future. This is where differences begin to show.
It's too soon to panic, but one company is currently in a much better spot for the long term.
10 stocks we like better than British American Tobacco ›
Sin stocks, such as tobacco companies, aren't for everyone, but they make excellent dividend stocks due to their entrenched and resilient business models and huge profit margins, which allow them to send most of their profits to shareholders.
Altria Group (NYSE: MO) and British American Tobacco (NYSE: BTI) are industry leaders with many similarities, including outsized dividends that yield around 7% at their current share prices.
But which company would be a better fit in your portfolio? The tobacco industry is evolving, and one company is adapting better.
Here is what you need to know.
Altria and British American Tobacco sell many of the leading brands of cigarettes and other tobacco products. Altria operates primarily in the U.S., where it sells Marlboro cigarettes. British American Tobacco sells globally, where it competes mainly with Philip Morris International in non-U.S. markets.
Investors looking at the financials will quickly notice that these two stocks are strikingly similar. Altria and British American Tobacco have nearly identical dividend yields, anticipated long-term earnings growth, and trade at almost the same valuation.
Essentially, both companies are slow-growing, high-yield dividend stocks.
You can also count on both companies to continue paying and raising their dividends. Both companies generate enough free cash flow to cover their dividends, and they have multibillion-dollar stakes in other companies that they can liquidate to raise cash.
Altria owns a stake in Anheuser-Busch InBev, worth approximately $11 billion at the company's current price. British American Tobacco owns a roughly 25% stake in ITC Limited, an Indian conglomerate worth approximately $16 billion today.
Despite the slow demise of traditional cigarettes, tobacco companies have become excellent financial survivalists.
Modern society is aware of the health dangers of smoking, which is why cigarette use has been in decline for years.
Tobacco companies know this and have spent the past decade rushing to develop and launch smokeless nicotine products that aren't healthy by any means but don't produce the harmful smoke cigarettes do. The big three product categories are electronic cigarettes/vapes, oral nicotine pouches, and heat-not-burn tobacco devices.
The tobacco industry is becoming the nicotine industry, and market share is up for grabs as consumers transition from cigarettes to smokeless products. Both companies, directly or through joint ventures, have established offerings in all three smokeless categories.
British American Tobacco has thrived with its electronic vape brand, Vuse, with an estimated 40% market share in its core markets. Sales of new product categories represented 13.2% of total revenue in 2024.
Altria is much further behind. In 2018, the company invested $12.8 billion in a fast-growing electronic vape company, but the investment was a disaster that set the company back. Altria has worked on alternative plans since then, but sales of new product categories totaled just $300 million in 2024, only 1.2% of total revenue.
While both companies should continue to squeeze value out of their cigarette businesses, Altria's long-term growth is currently on shakier ground.
Philip Morris International is rolling out its leading heat-not-burn brand, IQOS, in the United States. IQOS offers a similar experience to cigarettes and has successfully converted smokers in other countries. If IQOS thrives and Marlboro's cigarette declines accelerate, it could further pressure Altria.
Meanwhile, the U.S. government has begun cracking down on illegal vape products that have flooded the market. It's a win for Altria and British American Tobacco, but the latter should benefit more since Vuse already enjoys a whopping 50% share of the U.S. vaping market.
Altria doesn't seem poised to enjoy the same market leadership with these next-generation nicotine products that it has for generations with Marlboro cigarettes. Unless that changes, Altria's business may grow weaker over time as cigarette volumes erode.
Change is happening slowly, so Altria can still be an excellent short-term dividend stock. However, British American Tobacco is the superior high-yield stock to buy and hold.
Before you buy stock in British American Tobacco, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and British American Tobacco wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $651,761!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $826,263!*
Now, it's worth noting Stock Advisor's total average return is 978% — a market-crushing outperformance compared to 170% for the S&P 500. Don't miss out on the latest top 10 list, available when you join .
See the 10 stocks »
*Stock Advisor returns as of May 19, 2025
Justin Pope has no position in any of the stocks mentioned. The Motley Fool recommends British American Tobacco P.l.c. and Philip Morris International and recommends the following options: long January 2026 $40 calls on British American Tobacco and short January 2026 $40 puts on British American Tobacco. The Motley Fool has a disclosure policy.
Better High-Yield Dividend Stock: Altria or British American Tobacco? was originally published by The Motley Fool
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
24 minutes ago
- Yahoo
Is AbbVie the Best Dividend Stock in Big Pharma Today?
AbbVie Inc. (NYSE:ABBV) is one of the best dividend stocks for a bear market. The company holds the title of a Dividend King, having raised its dividend for 52 straight years. That kind of track record makes a dividend cut highly unlikely, as it would break the streak and potentially take decades to regain entry into this elite group. A pharmacist handing out a pharmaceutical drug to a patient in a drug store or chemist. AbbVie Inc. (NYSE:ABBV) is a leading pharmaceutical company with a strong product lineup that consistently delivers solid revenue and earnings. Its top growth drivers, Skyrizi and Rinvoq, have outperformed expectations, leading management to raise their combined 2027 sales forecast to over $31 billion. The company also benefits from other key products like Botox and a deep pipeline of new therapies to offset future patent expirations. With strong cash flow and a reliable portfolio, AbbVie Inc. (NYSE:ABBV) remains an attractive pick for income investors looking for long-term dividend stability. Naturally, if AbbVie encounters serious challenges, it could be pressured to reduce its dividend. One concern is its elevated payout ratio, currently at 267.66%. Typically, when a company's payout ratio remains above 70% for an extended time, it raises the risk of a dividend cut or suspension. However, AbbVie Inc. (NYSE:ABBV)'s next-generation immunology drugs are seeing strong growth, which could help offset the challenges it's facing from Humira. The rheumatoid arthritis treatment has been under pressure due to its loss of market exclusivity in the US and the increasing competition from biosimilars. ABBV currently offers a dividend yield of 3.5%, which is above S&P's average dividend yield of 1.3%. While we acknowledge the potential of ABBV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
5 hours ago
- Yahoo
Citi Increases PT on Oracle (ORCL), Keeps Neutral
Oracle Corporation (NYSE:ORCL) is one of the 10 software stocks analysts are upgrading. On June 12, Citi raised the price target on the company's stock to $196 from $186, while keeping a 'Neutral' rating. The firm believes that Oracle Corporation (NYSE:ORCL)'s Q4 2025 results are incrementally positive considering fiscal 2026 demand. That being said, the company's near-term earnings and FCF estimates have been falling. A team of IT professionals meticulously crafting a large-scale enterprise performance management system. As per Citi, Oracle Corporation (NYSE:ORCL) posted a strong Q4 2025, while it saw modest bookings growth. However, this was overshadowed by a strong fiscal 2026 sales outlook amidst accelerating cloud, remaining performance obligation, and total revenue growth, added the analyst. Oracle Corporation (NYSE:ORCL) expects its total cloud growth rate, applications plus infrastructure, to increase from 24% in FY 2025 to more than 40% in FY 2026. Notably, the Cloud Infrastructure growth rate is anticipated to increase from 50% in FY 2025 to more than 70% in FY 2026, while RPO is projected to grow over 100% in FY 2026. Also, Oracle Corporation (NYSE:ORCL) anticipates triple-digit MultiCloud revenue growth to continue in FY 2026. Ariel Investments, an investment management company, released its Q1 2025 investor letter. Here is what the fund said: 'Lastly, global leader in enterprise software, Oracle Corporation (NYSE:ORCL), traded lower alongside the broader technology sector due to macroeconomic uncertainty and in particular, the near-term prospects for artificial intelligence investment (AI) spending. As a result, ORCL reported weaker than expected quarterly earnings results. Nonetheless, management expects double-digit growth for fiscal 2026 and 2027, citing significant demand for its cloud and AI capabilities. This supports our view that ORCL's positioning as the leading provider of database software and cloud-based infrastructure is entrenched, making it a key beneficiary of global demand for generative AI development.' While we acknowledge the potential of ORCL to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ORCL and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now Disclosure: None.
Yahoo
8 hours ago
- Yahoo
Zeta Global (ZETA) Jumps 12.6% on Untapped AI Opportunities
Zeta Global Holdings Corp. (NYSE:ZETA) is one of the Zeta Global Holdings rallied by 12.63 percent on Friday to end at $14.18 apiece as investors snapped up shares following a study that marketing companies are lagging behind AI execution vis-a-vis its ambitions. In its study called 'It's Time to Get Serious About AI's Business Value,' Zeta Global Holdings Corp. (NYSE:ZETA) said that while many marketing organizations have begun implementing AI, most are still in the early stages of building the data, skills and systems required to scale it effectively and realize its full enterprise potential. Based on a survey of 300 North American marketing technology decision-makers, the study found that 62 percent of organizations described their current AI deployment as 'limited' or 'moderate.' The study was viewed by investors as a huge potential and opportunity for Zeta Global Holdings Corp. (NYSE:ZETA) to tap. 'Marketing should be at the front lines of the AI revolution, but many teams are held back by fragmented data, legacy systems, and skills gaps,' said Chairman and CEO David Steinberg. A marketing manager looking at the data dashboard of a marketing automation software showing successful campaign results. 'This study reinforces what we hear every day: marketers don't need more AI promises; they need practical, scalable ways to turn AI into better performance.' While we acknowledge the potential of ZETA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
